We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Trellis to Provide Cell Line Development Services to PDL BioPharma
News

Trellis to Provide Cell Line Development Services to PDL BioPharma

Trellis to Provide Cell Line Development Services to PDL BioPharma
News

Trellis to Provide Cell Line Development Services to PDL BioPharma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Trellis to Provide Cell Line Development Services to PDL BioPharma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Trellis Bioscience has announced that it has signed an agreement with PDL BioPharma to provide cell line development services using Trellis' Antibody CellSpot™ technology.

Antibody CellSpot™ allows for in-depth analysis and characterization of millions of individual antibody-producing cells for multiple properties, such as the affinity, specificity and secretion rate, and is coupled to a proprietary method for harvesting single cells.

The platform can screen diverse libraries of cells at an unprecedented level of depth and detail and operates with a simplicity and speed that can shave months from the normal development and manufacturing cycle for an antibody candidate.

"Our work with PDL BioPharma will allow us to demonstrate the power of CellSpot™," said Nolan Sigal, M.D., Ph.D., President of Trellis Bioscience.

"PDL BioPharma is a world leader in the discovery and development of antibodies, and we are excited to be working with them."

Advertisement